A light brush of fabric against skin should not cause agony. But for the roughly 51 million American adults living with chronic pain, that is often exactly what happens. Now, a study published in May 2026 points to a surprisingly small patch of brain tissue that may explain why some pain refuses to quit long after an injury has healed.
The culprit, according to research published in The Journal of Neuroscience by a team at the University of Colorado Boulder, is the caudal granular insular cortex, or CGIC, a subregion of the brain’s insula buried deep beneath the temporal lobe. The researchers found that a neural pathway running from the CGIC to the primary somatosensory cortex (S1) is necessary for neuropathic allodynia, the condition in which an innocuous touch registers as searing pain. When they disrupted that pathway in rats with nerve injuries, the allodynic behavior dropped sharply.
A feedback loop that locks pain in place
The finding did not emerge in isolation. Earlier work had already shown that lesioning the CGIC itself produced long-lasting relief from allodynia in rats with sciatic nerve damage, establishing the region as necessary for maintaining neuropathic pain behavior in that model. The new study goes further by identifying the specific downstream target: S1, the cortex responsible for mapping where on the body a sensation occurs and how intense it feels.
A review in Neuroscience Bulletin synthesizing animal and human evidence lays out the proposed circuit in detail. Pain signals travel from the spinal cord up to the CGIC via the thalamus. The CGIC then activates S1, and S1 sends signals back down to the spinal cord, creating a self-reinforcing loop. Once that loop locks in, pain persists even after the original tissue damage has resolved. The injury heals; the alarm keeps ringing.
Cross-species anatomy supports the model. Tract-tracing research in long-tailed macaque monkeys, published in the Journal of Comparative Neurology, showed that thalamic neurons in the posterior portion of the ventral medial nucleus project directly to the posterior insular cortex, confirming it as a primary recipient of pain-related inputs from the thalamus. Electrophysiology work in rats, also published in The Journal of Neuroscience, demonstrated that nociceptive thalamic neurons in the posterior triangular thalamus project to granular insular and secondary somatosensory regions. Together, these studies position the CGIC not as a passive bystander responding to general arousal but as an active participant wired directly into the pain pathway.
What makes this line of research notable is its specificity. Chronic pain has long been described in broad terms: sensitized nerves, overactive brain regions, psychological amplification. The CGIC-S1 circuit offers something more concrete: a defined pathway with identifiable nodes. In rodent models, interrupting that pathway blunted neuropathic pain behavior without eliminating other forms of sensory processing, suggesting the circuit has a degree of functional selectivity that could, in theory, be targeted without wiping out normal sensation.
Why the picture is still incomplete
The strongest evidence for the CGIC’s role comes from rats, and the gap between a rodent brain and a human one is not trivial. A commentary in Nature Neuroscience places the dorsal posterior insula in the context of human pain specificity but carefully distinguishes what has been demonstrated in people from what has been shown only in rodent CGIC circuitry. The human insula is anatomically similar but not identical, and no clinical study has yet tested whether disrupting a CGIC-equivalent pathway in a patient would relieve chronic pain.
A case report published in Brain Structure and Function complicates the picture further. It describes a patient with extensive bilateral damage to the insula, anterior cingulate, and amygdala who nonetheless retained emotional awareness of pain. If the insula were the sole gatekeeper of pain experience, that preservation would be difficult to explain. The case, though limited to a single patient, suggests that other brain regions can compensate, or that the subjective suffering of pain involves distributed networks extending well beyond any one cortical area.
There are also unresolved questions about causality. The rodent studies show that interrupting the CGIC-S1 circuit after nerve injury lessens allodynia, but they do not fully settle whether abnormal activity in this circuit is the initial trigger for chronic pain or a downstream consequence of broader nervous system changes. Plasticity in the spinal cord, thalamus, and other cortical regions likely interacts with CGIC signaling in ways that current experiments only partially capture.
And the clinical pipeline is empty. No trial data or regulatory filings exist for therapies targeting the CGIC-S1 pathway in humans. Researchers have not yet published human neuroimaging studies directly testing whether activity in a CGIC-equivalent area predicts who will transition from acute to chronic pain. Without that data, claiming this pathway could reliably prevent or reverse chronic pain in the clinic remains premature.
What the evidence can and cannot support
For readers trying to gauge what this research means, it helps to separate three levels of claim. At the level of basic neuroscience, the evidence that CGIC neurons receive pain-related input and influence S1 activity in rodents is strong, built on controlled lesion studies, electrophysiology recordings, and anatomical tract-tracing across species. At the level of disease modeling, the data showing this circuit is necessary for maintaining neuropathic allodynia in rats are compelling but still limited to specific injury types. At the level of human therapy, there is currently no direct evidence that altering a homologous circuit in people would safely and reliably treat chronic pain.
That hierarchy matters. It is accurate to say researchers have pinpointed a specific insular subregion and pathway that appear to sustain neuropathic pain in animal models. It is not yet accurate to say they have found a switch that can be flipped in patients. The existing studies justify deeper investigation, not immediate clinical application.
Where the research goes from here
Future work will likely move along several tracks simultaneously. In basic science, techniques such as optogenetics and cell-type-specific recordings can probe which neuronal populations within the CGIC are most critical for allodynia and how they change over time after injury. Comparative connectivity studies across species may clarify how closely the human posterior insula mirrors the rodent CGIC.
On the translational side, noninvasive imaging in patients with acute injuries could test whether heightened activity in dorsal posterior insula areas predicts who goes on to develop chronic pain. If consistent patterns emerge, they could justify cautious trials of targeted neuromodulation, using methods like focused ultrasound or deep brain stimulation, to modulate activity in these circuits. Any such trials would need to weigh potential pain relief against the risk of disrupting other insula-mediated functions, including interoception, emotional processing, and risk evaluation.
The stakes are high. Current frontline treatments for chronic pain remain limited. Opioids carry well-documented risks of dependence and diminishing returns. Physical therapy and cognitive behavioral therapy help many patients but do not resolve the underlying neural dysfunction. A targetable circuit, if validated in humans, could open the door to interventions that address the root mechanism rather than masking symptoms.
For now, the CGIC story is best understood as a mechanistically rich lead, not a finished solution. It sharpens the search for chronic pain’s biological underpinnings from vague “pain centers” to a specific, testable circuit. But pain is a whole-person phenomenon, shaped by neural wiring, emotional history, and social context. Even if the CGIC-S1 loop proves to be a key node, effective treatment will almost certainly require approaches that address both the circuitry and the life around it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
